TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02967094
Drug: Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04324918
Drug: HCP1102
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
Study: NCT04324918
Drug: HGP1408
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
Study: NCT03897868
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01309841
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg oral tablet once daily
Study: NCT01309841
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral tablet once daily
Study: NCT01309841
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet once daily
Study: NCT02119234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02407041
Drug: GR-MD-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00213161
Drug: iron supplement, iron drops
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01259973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
Study: NCT01374217
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin will be administered as it was prior to study entry.
Study: NCT01011452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
Study: NCT03428685
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos will be prescribed from 12 - 36+6 weeks.
Study: NCT02486211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT02781454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00673894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 30g +placebo (matching sitagliptin 100 mg)
Study: NCT04309669
Drug: TOT'HEMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: three ampoules per day during 12 weeks
Study: NCT00493974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 4 x daily
Study: NCT00326417
Drug: Cyclophosphamide 150mg
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
Study: NCT00326417
Drug: Cyclophosphamide 100mg
Normalized name: CYCLOPHOSPHAMIDE 100MG/VIL INJ
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
Study: NCT00326417
Drug: Cyclophosphamide 50mg
Normalized name: CYCLOPHOSPHAMIDE 50MG TAB
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
Study: NCT04367441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
Study: NCT01213368
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablets~Route of administration: oral
Study: NCT02183623
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00405821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily for 24 months
Study: NCT03896113
Drug: Celecoxib 200mg capsule
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
Study: NCT00835419
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
Study: NCT01283997
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
Study: NCT01116687
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01825980
Drug: BZF961
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
Study: NCT01825980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00673686
Drug: Yasminelle (SH T 00186 D)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
Study: NCT01615796
Drug: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive a single dose of GSK2140944
Study: NCT01615796
Drug: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
Study: NCT03520439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
Study: NCT03117530
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
Study: NCT02592395
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous
Study: NCT00880763
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to vaniprevir oral capsule twice daily for 28 days
Study: NCT00267371
Drug: Medical management/current medications per standard of care by personal physician.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management with current medications per standard of care by personal physician.
Study: NCT00253318
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg orally on Days 1 and 8.
Study: NCT00905723
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg daily for 6 months
Study: NCT00905723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill daily for six months
Study: NCT04157868
Drug: rhBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
Study: NCT00839423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, daily, orally
Study: NCT00003194
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04733001
Drug: HSG4112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT01188525
Drug: 10 parents drugs adminstration
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
Study: NCT00980785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT02924688
Drug: FF/UMEC/VI (100/31.25/25) mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
Study: NCT02924688
Drug: FF/UMEC/VI (100/62.5/25) mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
Study: NCT02924688
Drug: FF/UMEC/VI (200/31.25/25) mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
Study: NCT02924688
Drug: FF/UMEC/VI (200/62.5/25) mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
Study: NCT02924688
Drug: FF/VI (100/25) mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Study: NCT02924688
Drug: FF/VI (200/25) mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Study: NCT00648141
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule once daily for 12 weeks
Study: NCT00648141
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule twice daily for 12 weeks
Study: NCT00648141
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg oral capsule twice daily for 12 weeks
Study: NCT04462536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle only
Study: NCT02152358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01969942
Drug: Clyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02574858
Drug: QRH-882260
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
Study: NCT01596530
Drug: Drug-AZD8931
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug for biological activity
Study: NCT01596530
Drug: Drug-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator for biological activity comparison
Study: NCT04899960
Drug: Clinical Pharmacist Intervention
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
Study: NCT02570529
Drug: Albis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
Study: NCT02570529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
Study: NCT01848639
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
Study: NCT01848639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
Study: NCT00114270
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00797485
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00797485
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00797485
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02487277
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05008068
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin with PRF at site of osteotome
Study: NCT01734707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Allicor 150 mg tablet
Study: NCT01712217
Drug: AT13387
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSP90 inhibitor
Study: NCT02452112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch to be placed on the site of pain
Study: NCT00571688
Drug: Treatment as usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
Study: NCT03409419
Drug: [18F] CFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
Study: NCT04372342
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil
Study: NCT01684475
Drug: CJH1 (CLR4001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04584853
Drug: Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care endocrine therapy for a minimum of 5 years from randomisation
Study: NCT02190747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01612377
Drug: Prednisolone-Dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, QD
Study: NCT01508494
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01570478
Drug: Foster® NEXThaler® 100/6 µg/unit dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
Study: NCT01570478
Drug: Seretide® Accuhaler® 250/50 µg/actuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
Study: NCT00430963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01978509
Drug: Moderate volume prep (Moviprep)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
Study: NCT03537352
Drug: Any appropriate drug or non-drug treatment excluding surgery
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
Study: NCT01896388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01078714
Drug: bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
Study: NCT01700985
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied twice daily for two weeks
Study: NCT02790671
Drug: DS-8500a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 25mg tablet
Study: NCT01788982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02180217
Drug: LCI699 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
Study: NCT00744016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning
Study: NCT02188719
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
Study: NCT01214941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be given orally placebo twice a day for 5 days prior to the study.
Study: NCT01578785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
Study: NCT01273389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
Study: NCT02993913
Drug: Simmiparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simmiparib Tablets, oral administration
Study: NCT00255099
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 100 mg tablets b.i.d. / 96 weeks
Study: NCT00255099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets b.i.d. / 96 weeks
Study: NCT01033487
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral inhaled formulation, single dose
Study: NCT04465123
Drug: Spironolactone or hydrochlorothiazide
Normalized name: hydrochlorothiazide / spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours.
Study: NCT04465123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours.